Actively Recruiting
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Led by Ascentage Pharma Group Inc. · Updated on 2025-12-16
40
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
Sponsors
A
Ascentage Pharma Group Inc.
Lead Sponsor
S
Suzhou Yasheng Pharmaceutical Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
CONDITIONS
Official Title
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of systemic lupus erythematosus for at least 6 months
- On stable treatment for systemic lupus erythematosus for at least 28 days before first dose
- SLEDIA-2000 score between 4 and 12
- Generally good health aside from systemic lupus erythematosus
You will not qualify if you...
- Severe systemic lupus erythematosus
- Significant autoimmune disease other than lupus
- Significant, uncontrolled or unstable disease in any organ
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital Shanghai Jiaotong University School of Medical
Shanghai, Shanghai Municipality, China, 200127
Actively Recruiting
Research Team
Y
Yifan Zhai
CONTACT
X
Xiaofeng Han
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here